Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666078 | 0.84 | GCGR (0.41) | GCGRALDH1A1LMNAMAPK1ATM | |
| SCHEMBL2650034 | 0.79 | GCGR (0.57) | GCGRALDH1A1RAB9ANPC1POLB | |
| SCHEMBL2658305 | 0.76 | ALDH1A1 (0.47) | ALDH1A1RAB9ANPC1POLBLMNA | |
| SCHEMBL2648159 | 0.76 | GCGR (0.68) | GCGRALDH1A1RAB9ANPC1POLB | |
| SCHEMBL2648328 | 0.74 | GCGR (0.64) | GCGRLMNA | |
| SCHEMBL2650404 | 0.74 | GCGR (0.72) | GCGRALDH1A1RAB9ANPC1POLB | |
| SCHEMBL4040586 | 0.73 | GCGR (0.51) | GCGRALDH1A1RAB9ANPC1POLB | |
| SCHEMBL4045910 | 0.71 | GCGR (0.60) | GCGRALDH1A1RAB9ANPC1POLB | |
| SCHEMBL4040577 | 0.70 | GCGR (0.59) | GCGRALDH1A1RAB9ANPC1POLB | |
| SCHEMBL4040868 | 0.70 | GCGR (0.48) | GCGRALDH1A1RAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060035958-A1 | Method of treating diabetes and related conditions | MERCK & CO., INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1538903-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024066-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035958-A1 | Method of treating diabetes and related conditions | GLP1R, GPR119, GCGR | GCGR 3/4885ALDH1A1 2972/4885RAB9A 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.